| Literature DB >> 36050454 |
Chung-Yuan Liao1,2, Li-Chieh Wang1, Jyh-Hong Lee1, Kuan-Wen Wu1,3, Yu-Tsan Lin1, Yao-Hsu Yang1, Bor-Luen Chiang1,4, Hsin-Hui Yu5.
Abstract
Growing pains (GP), a common and benign pain syndrome of unknown etiology, is characterized by bilateral recurrent leg pain in childhood. There are no standardized diagnostic criteria for GP, and the diagnosis is often made by exclusion. To identify clinical and laboratory features, we included patients < 12 years with GP at National Taiwan University Children's Hospital between April 2006 and April 2019 in a retrospective study. We also compared body weight and body height z-scores between diagnosis and up to 2 years post-diagnosis to determine if rapid growth was associated with GP. This cohort study included 268 patients with a mean age of 4.7 ± 2.2 years. The most common features of GP were bilateral leg pain, no limitation of activity, intermittent pain, normal physical examination, and being well physically. The average number of Walters' criteria fulfilled by the patients with GP was 6.7 ± 0.9. Elevated serum levels of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) were observed in 37.5% and 15.6% of patients, respectively. Symptomatic medications were used in 33% of patients. Our study indicates that ALP and LDH may be biomarkers associated with GP. There was no significant association between GP and rapid growth within 2 years of diagnosis.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36050454 PMCID: PMC9436948 DOI: 10.1038/s41598-022-19285-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1Study flow chart.
Figure 2Percentage of fulfillment, likely fulfillment, and no fulfillment of ten Walters's criteria of growing pains.
Demographic and clinical characteristics of children with growing pains.
| N (%) or values | |
|---|---|
| Total number of patients | 268 (100) |
| Male | 146 (54.5) |
| Age, years | 4.65 ± 2.17 (1.17–12.39) |
| Body weight, kg | 18.52 ± 6.95 (9.5–66.0) |
| Body height, cm | 105.47 ± 14.91.08 (80.0–153.0) |
| BMI, kg/m2 | 16.04 ± 3.11 (13.2–28.19) |
| Bilateral pain | 226 (84.3) |
| Onset of pain | |
| Morning | 7/163 (4.3) |
| Afternoon | 5/163 (3.1) |
| Night | 151/163 (92.6) |
| Location of pain | |
| Upper limbs | 12 (4.5) |
| Lower limbs | 268 (100) |
| Limitation of activity | 0 (0) |
| Plain film | 65 (24.3) |
| Laboratory tests | 72 (26.9) |
| Observation only | 181 (67.5) |
| Oral medications only | 34 (12.7) |
| Topical medications only | 50 (18.7) |
| Both oral and topical medications | 3 (1.1) |
| Follow-up | 70 (26.1) |
BMI body mass index.
*The values are expressed as mean ± standard deviation (range).
Laboratory features in patients with growing pains.
| Parameter | Number, n | Mean value* | Elevated, n (%) |
|---|---|---|---|
| WBC (k/μL) | 70 | 8.31 ± 2.33 | 3 (4.3) |
| Hemoglobin (g/dL) | 69 | 12.89 ± .0.91 | 7 (10.1) |
| Platelet (k/μL) | 69 | 337.90 ± 83.40 | 6 (8.7) |
| CRP (mg/dL) | 53 | 0.10 ± 0.23 | 0 (0) |
| ESR (mm/h) | 45 | 10.06 ± 7.58 | 0 (0) |
| LDH (U/L) | 45 | 397.53 ± 208.45 | 7 (15.6) |
| AST (U/L) | 25 | 32.88 ± 9.18 | 4 (16.0) |
| ALT (U/L) | 21 | 13.24 ± 4.79 | 0 (0) |
| CK (U/L) | 19 | 107.89 ± 29.09 | 0 (0) |
| ALP (U/L) | 16 | 308.31 ± 159.76 | 6 (37.5) |
| C3 (mg/dL) | 49 | 113.65 ± 19.61 | 0 (0) |
| C4 (mg/dL) | 49 | 20.88 ± 7.76 | 0 (0) |
| ANA | 49 | 3 (6.1) | |
| RF (IU/mL) | 24 | All negative | |
| HLA-B27 | 5 | All negative |
WBC white blood count, CRP C-reactive protein, ESR erythrocyte sedimentation rate, LDH lactate dehydrogenase, AST aspartate aminotransferase, ALT alanine aminotransferase, CK creatine kinase, ALP alkaline phosphatase, C3 Complement 3, C4 Complement 4, ANA antinuclear antibodies, RF rheumatoid factor, HLA-B27 human leukocyte antigen B27. The values are expressed as mean ± standard deviation.
Figure 3Changes in body height z-scores at different time intervals from diagnosis of growing pains (GP). The time interval is defined as the time elapsed between diagnosis of GP and record of body height at another visit, with 0 being the point at which GP was diagnosed. Paired samples t-test showed no significant differences in body height z-scores between the time of diagnosis and prior or subsequent time points: (a) 1 year before the diagnosis of GP, (b) 6 months after diagnosis, (c) 1 year after diagnosis, and (d) 2 years after diagnosis.